Skip to main content
Go to homepage

Bruce H. Cohen, MD, FAAN

Director, NeuroDevelopmental Science Center; Interim Vice President and Medical Director, Rebecca D. Considine Research Institute; Pediatric Neurologist

Cohen, Bruce H., MD, pediatric neurologist

Before joining Akron Children’s, Dr. Cohen served as chief of pediatric neurology for Cleveland Clinic. He received his medical degree from the Albert Einstein College of Medicine and completed his pediatric residency at Children’s Hospital of Philadelphia, pediatric neurology residency at Columbia Presbyterian Medical Center and his American Cancer Society neuro-oncology fellowship in Philadelphia.

Medical Service / Department / Program:

View details and comments

NeuroDevelopmental Science Center
Rebecca D. Considine Research Institute

In his work to uncover treatments for patients with mitochondrial diseases, Dr. Cohen has become one of the world’s leading experts. Although there are no cures for mitochondrial diseases, Dr. Cohen looks for one every day. As a result of his work and our hospital’s commitment to helping him build an infrastructure for conducting mitochondrial clinical trials, Akron Children’s is one of the country’s leading institutions researching treatments.

Medical School:
Albert Einstein College of Medicine of Yeshiva University, Bronx, NY
Residency:
Pediatrics: Children's Hospital of Philadelphia, PA
Pediatric Neurology: Columbia Presbyterian Medical Center, New York, NY
Fellowship:
Pediatric Neuro-Oncology: Children's Hospital of Philadelphia, PA
Board Certifications:
American Board of Psychiatry and Neurology; Special Qualification in Child Neurology
Associations:
  • Fellow, American Academy of Neurology
  • Child Neurology Society
  • Mitochondrial Medicine Society
  • American Neurological Association
Clinical Interests:
mitochondrial disease research and treatment
  • Best Doctors in America 2019-2020 Logo
  • Best Doctors in America 2017-2018 Logo
  • Best Doctors 2015-2016

What are Patient Experience Star Ratings? Learn more.

What next?